GlassScriptPhysician profile
Robert Carracino
NPI 1093798571
$3,161.75
in general payments reported to CMS, 2019-2025
30 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $238 · 2021: $87.82 · 2022: $221 · 2023: $300 · 2024: $465 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $214.67 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $179.05 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $169.41 | 2022-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.91 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $153.68 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Allergan, INC. | $149.90 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.04 | 2019-2020 | |
| Pfizer INC. | $141.59 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.49 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $134.91 | 2019 | |
| Merck Sharp & Dohme LLC | $118.75 | 2019-2020 | |
| Corcept Therapeutics | $70.66 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $59.47 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $53.75 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.95 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $50.59 | 2019 | |
| Amarin Pharma, INC. | $43.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.12 | 2019 | |
| Abbott Laboratories | $35.73 | 2019-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $29.20 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $27.65 | 2024 | Nexletol |
| Lundbeck LLC | $21.51 | 2025 | Rexulti |
| Astellas Pharma US INC | $19.99 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $15.16 | 2023 | Camzyos |
| Phathom Pharmaceuticals, INC. | $14.05 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $14.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.74 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.06 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carracino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.